Hydroxyurea therapy for management of secondary erythrocytosis in cyanotic congenital heart disease

American Journal of Hematology

Volumn 82, Issue 8, 2007, Pages 740-743

  Reiss, Ulrike M ^a   Bensimhon, Pamela ^b   Zimmerman, Sherri A ^b   Ware, Russell E ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; HYDROXYUREA;

ADOLESCENT; ADULT; ARTICLE; BLOOD VISCOSITY; BONE MARROW SUPPRESSION; CASE REPORT; CONGENITAL CYANOTIC HEART MALFORMATION; CONGENITAL HEART DISEASE; CYANOSIS; DRUG DOSE REDUCTION; ERYTHROCYTE COUNT; ERYTHROCYTOSIS; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; IRON DEFICIENCY; MALE; MEAN CORPUSCULAR HEMOGLOBIN; MEAN CORPUSCULAR VOLUME; MORBIDITY; PHLEBOTOMY; PRIORITY JOURNAL; STROKE; SYMPTOMATOLOGY; TREATMENT RESPONSE;

ADOLESCENT; ADULT; FEMALE; HEART DEFECTS, CONGENITAL; HUMANS; HYDROXYUREA; MALE; POLYCYTHEMIA;

EID: 34547670574     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20925     Document Type: Article

References (35)

1. Kontras SB, Bodenbender JG, Craenen J, Hosier DM. Hyperviscosity in congenital heart disease. J Pediatr 1970;76:214-220.
2. Perloff JK, Rosove MH, Child JS, Wright GB. Adults with cyanotic congenital heart disease: Hematologic management. Ann Intern Med 1988;109:406-413.
3. Rudolph AM, Nadas AS, Borges WH. Hematologic adjustments to cyanotic congenital heart disease. Pediatrics 1953;11:454-465.
4. Engelfriet P, Boersma E, Oechslin E, et al. The spectrum of adult congenital heart disease in Europe: Morbidity and mortality in a 5 year follow-up period. The Euro Heart Survey on adult congenital heart disease. Eur Heart J 2005;26:2325-2333.
5. Oldershaw PJ, Sutton MG. Haemodynamic effects of haematocrit reduction in patients with polycythaemia secondary to cyanotic congenital heart disease. Br Heart J 1980;44:584-588.
6. Rosenthal A, Nathan DG, Marty AT, et al. Acute hemodynamic effects of red cell volume reduction in polycythemia of cyanotic congenital heart disease. Circulation 1970;42:297-308.
7. Cottrill CM, Kaplan S. Cerebral vascular accidents in cyanotic congenital heart disease. Am J Dis Child 1973;125:484-487.
8. Hutton RD. The effect of iron deficiency on whole blood viscosity in polycythaemic patients. Br J Haematol 1979;43:191-199.
9. Linderkamp O, Klose HJ, Betke K, et al. Increased blood viscosity in patients with cyanotic congenital heart disease and iron deficiency. J Pediatr 1979;95:567-569.
10. Phornphutkul C, Rosenthal A, Nadas AS, Berenberg W. Cerebrovascular accidents in infants and children with cyanotic congenital heart disease. Am J Cardiol 1973;32:329-334.
11. Schmid-Schonbein H, Wells RE, Jr. Rheological properties of human erythrocytes and their influence upon the "anomalous" viscosity of blood. Ergeb Physiol 1971;63:146-219.
12. Ballas SK, Dover GJ, Charache S. Effect of hydroxyurea on the rheological properties of sickle erythrocytes in vivo. Am J Hematol 1989;32:104-111.
13. Burns ER, Reed LJ, Wenz B. Volumetric erythrocyte macrocytosis induced by hydroxyurea. Am J Clin Pathol 1986;85:337-341.
14. De Bergsagel DE, Frenkel EP, Alfrey CP, Jr, Thurman WG. Megaloblastic erythropoiesis induced by hydroxyurea (NSC-32065). Cancer Chemother Rep 1964;40:15-17.
15. Cornu P. Long-term hematological management of cyanotic congenital heart diseases. Arch Mal Coeur Vaiss 1994;87:1413-1420.
16. Triadou P, Maier-Redelsperger M, Krishnamoorty R, et al. Fetal haemoglobin variations following hydroxyurea treatment in patients with cyanotic congenital heart disease. Nouv Rev Fr Hematol 1994;36:367-372.
17. Oechslin E. Hematological management of the cyanotic adult with congenital heart disease. Int J Cardiol 2004;97 (Suppl 1):109-115.
18. Thorne SA. Management of polycythaemia in adults with cyanotic congenital heart disease. Heart 1998;79:315-316.
19. Alter BP, Gilbert HS. The effect of hydroxyurea on hemoglobin F in patients with myeloproliferative syndromes. Blood 1985;66:373-379.
20. Engstrom KG, Lofvenberg E. Treatment of myeloproliferative disorders with hydroxyurea: Effects on red blood cell geometry and deformability. Blood 1998;91:3986-3991.
21. Stevens MR. Hydroxyurea: an overview. J Biol Regul Homeost Agents 1999;13:172-175.
22. Bridges KR, Barabino GD, Brugnara C, et al. A multiparameter analysis of sickle erythrocytes in patients undergoing hydroxyurea therapy. Blood 1996;88:4701-4710.
23. Oechslin E, Kiowski W, Schindler R, et al. Systemic endothelial dysfunction in adults with cyanotic congenital heart disease. Circulation 2005;112:1106-1112.
24. Hillery CA, Du MC, Wang WC, Scott JP. Hydroxyurea therapy decreases the in vitro adhesion of sickle erythrocytes to thrombospondin and laminin. Br J Haematol 2000;109:322-327.
25. Hankins JS, Ware RE, Rogers ZR, et al. Long-term hydroxyurea therapy for infants with sickle cell anemia: The HUSOFT extension study. Blood 2005;106:2269-2275.
26. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: Risks and benefits up to 9 years of treatment. JAMA 2003;289:1645-1651.
27. Zimmerman SA, Schultz WH, Davis JS, et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood 2004;103:2039-2045.
28. Silver RT. Treatment of polycythemia vera. Semin Thromb Hemost 2006;32:437-442.
29. O'Branski EE, Ware RE, Prose NS, Kinney TR. Skin and nail changes in children with sickle cell anemia receiving hydroxyurea therapy. J Am Acad Dermatol 2001;44:859-861.
30. Kersgard C, Osswald MB. Hydroxyurea and sickle cell leg ulcers. Am J Hematol 2001;68:215-216.
31. Charache S, Dover GJ, Moyer MA, Moore JW. Hydroxyurea-induced augmentation of fetal hemoglobin production in patients with sickle cell anemia. Blood 1987;69:109-116.
32. Ammash N, Warnes CA. Cerebrovascular events in adult patients with cyanotic congenital heart disease. J Am Coll Cardiol 1996;28:768-772.
33. Gidding SS, Stockman JA, III. Effect of iron deficiency on tissue oxygen delivery in cyanotic congenital heart disease. Am J Cardiol 1988;61:605-607.
34. Broberg CS, Bax BE, Okonko DO, et al. Blood viscosity and its relationship to iron deficiency, symptoms, and exercise capacity in adults with cyanotic congenital heart disease. J Am Coll Cardiol 2006;48:356-365.
35. Perloff JK, Marelli AJ, Miner PD. Risk of stroke in adults with cyanotic congenital heart disease. Circulation. 1993;87:1954-1959.